Envarsus (LCP-tacrolimus) is a once daily tacrolimus formulation that increases adherence and decreases side effects in children with organ transplants. Recently Veloxis, the drug company who produces and sells Envarsus, restricted the use of the Envarsus copay card to patients 18 years old and up. This has resulted in pediatric patients transitioning back to IR twice daily tacrolimus, negatively impacting patient care. We are working with leadership groups (CHA and PPA) to ask Veloxis to reverse this decision. The Envarsus copay card was available for pediatric patients for many years and there are other immunosuppressants not FDA labeled for pediatrics that have copay cards available to this population. Please respond if we can include your center in the list of centers requesting this decision be reversed to increase pediatric access to this medication. Thank you!

Nick Weaver & Carly Heyrend
Primary Children's Hospital
Salt Lake City, Utah